New Study Finds Many Preschoolers with ADHD Are Given Medication Quickly, Contrary to Guidelines

Updated on December 2, 2025, with new Latin American Spanish and Mandarin audio versions to help readers worldwide access this content.

🎧 ▶️ Press the play button below to listen in English.

🇪🇸 Spanish (Latinoamérica)

Hoy te cuento un nuevo hallazgo: muchos niños preescolares con TDAH están recibiendo medicamentos demasiado rápido, a pesar de lo que recomiendan las guías clínicas.

Presiona el botón de reproducir para escuchar.

🇨🇳 中文（简体）

今天要分享一项新研究：许多学龄前的多动症儿童被过早使用药物治疗，这与指南建议并不一致。

请按下方的播放按钮收听。

Introduction: The Startling Prescription Trend

When a four-year-old is bursting with energy, unable to sit still, or struggles to follow directions, what are we witnessing? Is it a sign of a developing brain, full of normal childhood exuberance? Or are we seeing the early signs of Attention-Deficit/Hyperactivity Disorder (ADHD), a legitimate neurodevelopmental condition?

A major new study of children’s health records across the United States has cast a spotlight on this very question, revealing a startling reality: 42% of preschoolers diagnosed with ADHD are prescribed medication within just one month of their diagnosis. This practice often sidesteps established medical guidelines that recommend behavior therapy as the first and primary treatment.

This rapid move to medication raises profound and uncomfortable questions that go to the heart of children’s healthcare. 

What is ADHD, and how do we distinguish it from simply being a spirited, young child? Are all the children being prescribed powerful stimulant medications truly affected by a clinical disorder, or could some be falling victim to pathologization—the process of treating normal, range-of-human behavior as a medical problem?

And ultimately, what does this trend tell us about why American children are among the most heavily medicated in the world?

The answers are not simple, but this new research provides critical clues, pointing to a healthcare system where the easiest solution is often a pill, even for our youngest and most vulnerable.

II. What Exactly is ADHD? A Quick Primer

To understand the debate, we first need to understand what ADHD is—and what it is not.

A. The Clinical Definition

ADHD is not a simple label for a child who misbehaves. It is a recognized neurodevelopmental disorder, meaning it’s linked to the brain’s biology and wiring. Clinically, it’s defined by a persistent and impairing pattern of three core behaviors:

1. Inattention: Difficulty sustaining focus, being easily distracted, making careless mistakes, and struggling to follow through on instructions.
2. Hyperactivity: Seemingly constant, excessive motor activity, like fidgeting, tapping, or running and climbing in inappropriate situations.
3. Impulsivity: Taking actions without thinking, having difficulty waiting for a turn, and frequently interrupting others.

B. The Key Differentiator: It’s About Impairment, Not Just Energy

The crucial difference between a child with ADHD and a typically energetic child lies in the degree and impact of these behaviors. For a diagnosis to be made, these symptoms must be:

• Persistent: Lasting for at least 6 months.
• Pervasive: Showing up in multiple settings (e.g., at home, at school, and during playdates).
• Disruptive: Significantly interfering with a child’s social, academic, or emotional functioning.

In short, ADHD is not just about having energy; it’s about the brain’s inability to regulate that energy, attention, and impulses in a way that allows the child to navigate their world successfully.

III. The Blurry Line: When Does “Normal” Become a “Disorder”?

This clinical definition of ADHD begs a critical question that parents and doctors grapple with daily: where is the line between a child with a neurodevelopmental disorder and a child who is simply… being a child? For preschoolers, this line is especially blurry.

A. Normal Preschooler Behavior: The “Look-Alikes”

Many of the hallmark behaviors of ADHD are, in fact, completely typical and developmentally appropriate for 3-to-5-year-olds. This is why diagnosis at this age is so challenging. Consider these common traits of healthy preschoolers:

• High Energy & Fidgeting: Running, climbing, and constant motion are natural ways young children explore their world and develop motor skills.
• Short Attention Spans: The ability to focus for extended periods is a skill that develops over time. It is normal for a preschooler to flit from one toy to another.
• Impulsivity & Lack of Self-Control: The part of the brain responsible for impulse control (the prefrontal cortex) is still under major construction during these years. A young child grabbing a toy or interrupting a conversation is often a sign of a developing brain, not a broken one.
• Not Following Directions: This can stem from forgetfulness, distraction, or simply not fully understanding multi-step commands, all of which are common at this age.

Beyond the Label: When “Symptoms” Look Like Genius

It’s a compelling thought experiment to look back at history through a modern lens. While we can never diagnose historical figures, the documented behaviors of many brilliant and influential individuals in their childhoods bear a striking resemblance to what we might now identify as ADHD symptoms. Their stories highlight that the energy, creativity, and non-linear thinking associated with ADHD can be powerful assets.

Albert Einstein: The archetype of the genius, Einstein was far from a model student in his youth. He was famously a late talker, which concerned his parents. He was described as quiet, withdrawn, and a daydreamer in school, often forgetting his lessons and failing to respond to instructions—all potential signs of inattention.

His revolutionary ideas, however, came from his ability to think in visual pictures and challenge established norms, a hallmark of a non-traditional, ADHD-like cognitive style.

Thomas Edison: As a child, Edison’s relentless curiosity was often mistaken for mischief. His teachers considered him “addled” and difficult, and his formal schooling lasted only a few months before his mother pulled him out to teach him at home.

He was constantly experimenting, asking questions, and tinkering—behaviors that could be seen as hyper-focus on his interests and impulsivity in his actions. This same restless mind went on to hold over 1,000 patents.

Simone Biles: The most decorated gymnast in history has openly spoken about having ADHD. As a child in foster care, her boundless energy was seen as a challenge. She has said she was “always bouncing off the walls.”

It wasn’t until she channeled that superhuman energy into gymnastics that the world saw it for what it was: not a deficit, but an unparalleled physical gift requiring immense focus and power.

Richard Branson: The founder of the Virgin Group has publicly discussed his dyslexia and ADHD. He struggled terribly in school, was considered a daydreamer, and had poor academic performance. His restless, risk-taking nature and inability to thrive in a traditional setting led him to drop out at 16.

He channeled his impulsivity and big-picture thinking into entrepreneurial ventures, building a global empire by seeing possibilities where others saw rules.

The Takeaway: The traits of a distractible, energetic, and unconventional child can be immensely challenging in a structured classroom. But these stories remind us that the same traits—when nurtured and channeled—can be the foundation for extraordinary creativity, innovation, and physical prowess.

The goal should not be to medicate a child into conformity simply, but to understand their unique mind and help them find the outlet where their “symptoms” become their superpowers.

B. The Critical Difference: Context is Key

So, how can we tell the difference? The distinction lies not in the presence of a single behavior, but in its severity, persistence, and impact.

• Normal: A child who can’t sit still during a 30-minute dinner but can become engrossed in building a complex block tower or listening to a favorite storybook for a reasonable amount of time.
• ADHD: A child who cannot focus on any activity, even those they highly enjoy, for more than a minute or two. Their hyperactivity and impulsivity constantly disrupt playgroups, make it unsafe to visit a park, and prevent them from engaging in any structured learning.

C. The Danger of Pathologizing Childhood

This is where the concept of pathologization becomes a real danger. Pathologization means treating a normal range of human behavior as if it were a medical disease or disorder. In our fast-paced, results-oriented society, there is immense pressure on children to “fit in” and conform to behavioral expectations in schools and daycare.

A spirited, energetic, or strong-willed child can be misinterpreted as a “problem” that needs to be fixed.

When we medicalize normal childhood exuberance, we risk labeling a child who is simply on a different developmental timeline. The consequence isn’t just a diagnosis; it’s that the child may be prescribed powerful psychoactive medications to manage their personality or immaturity, subjecting them to potential side effects without addressing the true nature of their behavior.

This underscores why the study’s finding of rapid medication use is so concerning—it raises the question of how many children are being medicated for being normally, actively three, four, or five years old.

IV. The New Study’s Findings: A Snapshot of US Care

The theoretical debate over the “blurry line” becomes starkly real when we examine the data from this recent study.  To understand the whole picture, it’s vital to grasp the scale of the research.

The findings are based on a deep analysis of electronic health records for 712,478 children who were seen in primary care practices across eight major US pediatric health systems between 2016 and 2023.

This wasn’t a small survey; it was a comprehensive look at the real-world care of nearly three-quarters of a million young children, giving an authoritative snapshot of current practices.

A. The Startling Numbers

The research, which analyzed electronic health records from eight major US pediatric health systems, revealed two key findings that concern many experts:

1. High Overall Medication Rate: Of the 9,708 preschoolers diagnosed with ADHD, a striking 68.2% were prescribed ADHD medication before they turned 7 years old. This means over two-thirds of these young children were placed on a drug-based treatment path.
2. Rapid Medication Initiation: Perhaps more alarming was the speed of treatment. The study found that 42.2% of these children received a prescription for ADHD medication within 30 days of their initial diagnosis. This practice leaves little to no time for the recommended first-line treatment—parent training in behavior management—to be attempted or evaluated.

B. The Disparities in Diagnosis and Treatment

The study further revealed that a child’s background significantly influenced their care, uncovering troubling disparities:

• Racial and Ethnic Gaps: The data showed that Asian, Hispanic, and Black children with ADHD were less likely to be prescribed medication early compared to their White peers. This suggests either greater barriers to care or greater cultural hesitation about medication within these communities.
• An Insurance Divide: Conversely, children with public insurance (like Medicaid) were more likely to receive an early prescription than those with private insurance. This points to a systemic failure, suggesting that publicly insured families may face such significant barriers to accessing behavioral therapy that medication becomes the default option.

These findings move the conversation beyond a simple question of over-medication. They suggest that the path to treatment in the US is heavily influenced by non-clinical factors—a child’s race, ethnicity, and economic status—raising serious questions about equity and the consistency of care.

V. The Clash: Guidelines vs. Reality

The study’s findings reveal a deep and troubling chasm between the established medical guidelines for treating young children with ADHD and what is actually happening in doctors’ offices across the United States. The “why” behind this gap is central to understanding the American trend of medicating the very young.

A. The Gold Standard: What Should Happen

The official recommendations from the American Academy of Pediatrics (AAP) are clear and unambiguous. For children aged 4 to 5 years, the first line of treatment should be evidence-based behavior therapy, specifically parent training in behavior management.

This approach does not involve medicating the child. Instead, it focuses on coaching parents to:

• Use positive reinforcement to encourage good behavior.
• Establish consistent routines and clear rules.
• Implement effective discipline strategies that do not involve yelling or spanking.
• Learn techniques to help their child manage their emotions and improve focus.

The guidelines recommend medication only if these behavioral interventions do not provide significant improvement, and even then, it should be prescribed cautiously. The philosophy is “skills before pills”—giving families the tools to manage behavior before turning to a pharmaceutical solution.

B. The Common Reality: What Does Happen

As the study demonstrates, the common reality is often the inverse of the guideline. For a large number of children, medication becomes the first step, not the last resort. This happens for several systemic reasons:

The “Quick Fix” vs. The “Hard-to-Access” Fix: A prescription for medication is relatively simple and fast.

A pediatrician can write it during a 15-minute appointment. In contrast, finding a qualified behavior therapist, navigating insurance coverage, and attending weekly sessions is a time-consuming, expensive, and often frustrating process for families.

Long waitlists are common. In a strained healthcare system, medication becomes the path of least resistance.

Pressure from Schools and Parents: Pediatricians often face pressure from schools and overwhelmed parents who need a rapid solution for a child who is disruptive in the classroom or difficult to manage at home. In the face of this urgency, the slower, more demanding path of behavior therapy can be sidelined.

The Gap in Specialist Access: As highlighted by the insurance disparity, families on public insurance have even greater difficulty accessing mental health specialists.

When the recommended first-line treatment is effectively out of reach, medication can appear to be the only viable option, even for doctors who would prefer to follow the guidelines.

This clash between ideal and real-world practice lies at the heart of the issue. We have a gold-standard guideline that is, for many, functionally impossible to follow, creating a system where medication becomes the default, not the deliberate choice.

VI. The Risk of Medicalizing Normalcy and The Path Forward

The study’s findings—of rapid, widespread medication use influenced by demographic factors—point toward a systemic tendency to medicalize childhood behavior. This approach carries significant risks and demands a more thoughtful path forward.

A. The Risk of Medicalizing Normalcy

When we frame developmentally normal, if challenging, behavior as a medical condition, we risk:

• Misdiagnosis and Unnecessary Treatment: Children who are simply energetic or immature may be mislabeled with a disorder and prescribed powerful medications they do not need, exposing them to potential side effects like appetite suppression, sleep problems, and slowed growth.
• Overlooking Root Causes: A focus on medication can distract from other critical factors influencing a child’s behavior, such as anxiety, stress at home, an inappropriate school environment, or simply needing more time to mature.
• The Loss of Potential: This is the most profound risk. When we medicate a child to suppress their natural energy and non-conformity, we may inadvertently be suppressing their unique potential.

---

The Potential Cost: If Genius Had Been “Treated”

It’s a sobering thought experiment to consider what might have been lost if the famous figures we mentioned had been medicated as children.

The goal of ADHD medication is to normalize neurodivergent traits—to reduce impulsivity, increase focus, and curb hyperactivity. In doing so, it can smooth out the very “edges” that, in the right context, become sources of brilliance and innovation.

1. Albert Einstein: The Daydreamer

What Might Have Been Lost: The Theory of Relativity.

The Reasoning: Einstein’s genius lay in his ability to conduct “thought experiments”—to visualize riding on a beam of light and question the fundamental nature of space and time.

This requires a mind that is free to wander, disconnect from immediate tasks, and ignore conventional instruction.

Medication aimed at improving his focus in a traditional classroom might have anchored his mind to the here-and-now, potentially dulling the very capacity for abstract, revolutionary daydreaming that changed physics forever.

2. Thomas Edison: The Restless Tinkerer

What Might Have Been Lost: The phonograph, the practical lightbulb, and the motion picture camera.

The Reasoning: Edison’s “failure” in school and his relentless, hands-on experimentation were two sides of the same coin. A medication that curbed his impulsivity and restless energy might have made him more compliant in a classroom, but it could also have suppressed his insatiable drive to take things apart, test thousands of filaments, and learn exclusively through direct action.

His process was messy, non-linear, and required a tolerance for repeated failure—traits often at odds with the goal of controlled behavior.

3. Simone Biles: The Powerhouse

What Might Have Been Lost: Her unprecedented athletic dominance.

The Reasoning: Biles’s “boundless energy” and hyperfocus are the engine of her talent. Medication that managed her hyperactivity might have also regulated the explosive, neuro-muscular intensity required to perform skills no other woman has ever attempted.

The mental and physical state needed to twist and flip through the air is intimately tied to a highly active, uniquely wired nervous system. Calming that system down might have calmed the very source of her power.

4. Richard Branson: The Rule-Breaker

What Might Have Been Lost: The Virgin Empire.

The Reasoning: Branson’s success is built on risk-taking, big-picture thinking, and a rejection of conventional paths. Medication aimed at helping him sit still and follow directions in school would have directly worked against his innate impulsivity and disdain for authority—the very traits that led him to start a magazine at 16, then an airline, and then a space tourism company.

A “well-managed” Branson might have become a successful but conventional businessman, not a transformative entrepreneur.

This is not an argument against medication for ADHD. For many children, the symptoms are so severe that they lead to academic failure, social rejection, and crushing low self-esteem. For them, medication can be life-changing, unlocking their ability to learn and function.

However, this thought experiment serves as a critical warning. It highlights that:

• The line between a “disorder” and a “gift” can be razor-thin, often determined by the environment and the outlet a child is given.
• The goal of treatment should not be mere conformity. The objective should be to alleviate true suffering while nurturing the unique strengths that often accompany the neurodivergent mind.
• Medication is a powerful tool, not a simple solution. Its use requires careful consideration of the whole child—not just their challenges, but their potential. The energy of a future Olympian, the daydreams of a future physicist, and the rebelliousness of a future innovator are all precious things that we must be careful not to lose in our quest for manageable behavior.

VI. A Symptom of a Larger System

A Broader Pattern: An American Medical Culture of Prescription

The findings of this study are not an anomaly confined to pediatric care. They reflect a deeply entrenched pattern in the American healthcare system as a whole: a heavy reliance on pharmaceutical solutions for complex human conditions.

Just as preschoolers are quickly prescribed stimulants, American adults are among the most heavily medicated populations in the world for psychoactive drugs.

• Antidepressants and Anti-anxiety medications are frequently prescribed to manage the stresses and challenges of modern life, sometimes as a first resort before or instead of comprehensive therapy and lifestyle interventions.
• Sleep aids are widely used, often bypassing the investigation and treatment of underlying causes of insomnia.

This “pill for every problem” approach is driven by the same systemic forces seen in the ADHD study:

• The 15-Minute Appointment: The structure of primary care, with its short visit times, favors writing a prescription over engaging in time-consuming counseling.
• Insurance Reimbursement: It is often easier and more profitable for a healthcare system to bill for a medication management visit than for prolonged behavioral therapy.
• Cultural Expectation: Patients and parents, influenced by direct-to-consumer drug advertising and a culture seeking quick fixes, often arrive at appointments expecting a prescription.

The rapid medication of young children for ADHD, therefore, can be seen as an extension of this established medical norm. We are applying an adult system’s preference for pharmaceutical efficiency to our youngest and most vulnerable citizens, raising the stakes immeasurably. The childhoods we are medicalizing today are the futures we are shaping for tomorrow.

VII. Conclusion: A Call for a More Nuanced Approach

The findings of this study reveal a healthcare landscape where medication has become the default response to challenging childhood behaviors, often bypassing recommended guidelines and overlooking the complex nature of child development.

What emerges is not a simple narrative of over-medication, but rather a troubling portrait of a system where pharmaceutical intervention has become the path of least resistance—for doctors facing time constraints, for parents navigating overwhelmed schools, and for a medical culture that often prioritizes efficiency over comprehensive care.

The Way Forward

Addressing this complex issue requires concerted effort across our healthcare system and society:

1. For the Healthcare System: We must fundamentally improve access to behavioral therapies by increasing insurance reimbursement rates for these services, training more child mental health specialists, and integrating behavioral health supports directly into pediatric primary care settings.
2. For Medical Education and Practice: Pediatricians need better training in distinguishing between clinical ADHD and developmentally appropriate behavior. They also need support systems that allow for longer appointment times and resources to guide families toward non-pharmaceutical interventions.
3. For Parents and Society: We must empower parents to ask crucial questions: “Is this truly ADHD?” “What are all our treatment options?” “Can we try behavioral approaches first?” As a society, we need to re-examine our expectations of young children and create environments—both in schools and at home—that can accommodate a wider range of normal developmental trajectories.

The goal cannot be simply to medicate children into conformity. Instead, we must strive to create a system that has the time, resources, and wisdom to distinguish between a disorder that needs treatment and a childhood that needs understanding.

In our urgency to manage difficult behavior, we must ensure we are not inadvertently suppressing the unique potential that often lies within it.

Don’t Get Sick!

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.

Related:

1. Serotonin Levels Do Not Correlate With Depression
2. Overcome Chronic Depression With Exercise, Healing Body And Mind
3. Fasting Vs. Depression: The Life-Changing Cure You Need Now
4. Rethinking SSRIs and the Serotonin Theory of Depression
5. Antidepressants And Chronic Disease: The Shocking Truth You Must Know!
6. How Exercise Improves Brain Health in Children with Obesity
7. Mental and Neurologic problems after COVID-19 in children and adults
8. Autism And Acetaminophen: New Evidence From Global Research
9. Imagine America Investing Billions In Health, Schools, Not War

References:

1. Bannett, Y., Luo, I., Azuero-Dajud, R., et al. (2025). ADHD Diagnosis and Timing of Medication Initiation Among Children Aged 3 to 5 Years. JAMA Network Open, 8(8): e2529610. doi:10.1001/jamanetworkopen.2025.29610
2. Wolraich, M. L., Hagan, J. F., Jr, Allan, C., et al. (2019). Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics, 144(4), e20192528.
   • This is the source of the official American Academy of Pediatrics (AAP) guidelines, which recommend behavior therapy as the first-line treatment for preschoolers.
3. Danielson, M. L., Bitsko, R. H., Ghandour, R. M., Holbrook, J. R., Kogan, M. D., & Blumberg, S. J. (2018). Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016. Journal of Clinical Child & Adolescent Psychology, 47(2), 199–212.
   • This reference provides a broader context on the national prevalence of ADHD diagnosis and treatment trends in the United States.
4. Shi, Y., Hunter Guevara, L. R., Dykhoff, H. J., et al. (2021). Racial Disparities in Diagnosis of Attention-Deficit/Hyperactivity Disorder in a US National Birth Cohort. JAMA Network Open, 4(3), e210321.
   • This study supports the discussion of racial and ethnic disparities in ADHD diagnosis, a key point in the article.
5. Coker, T. R., Elliott, M. N., Toomey, S. L., et al. (2016). Racial and Ethnic Disparities in ADHD Diagnosis and Treatment. Pediatrics, 138(3), e20160407.
   • Another key study detailing the disparities in how ADHD is diagnosed and treated across different racial and ethnic groups.
6. National Institute of Mental Health (NIMH). (2023). Attention-Deficit/Hyperactivity Disorder (ADHD).
   • This resource provides the standard clinical definition and diagnostic criteria for ADHD, used to explain the disorder in the article.
7. U.S. Centers for Disease Control and Prevention (CDC). (2023). Data and Statistics About ADHD.
   • The CDC is a primary source for national data on ADHD prevalence and treatment patterns, supporting the broader context of the article’s argument.
8. U.S. Food and Drug Administration (FDA). (2023). Medication Guides for Specific ADHD Medications.
   • The FDA provides official information on the uses, efficacy, and potential side effects of prescription stimulants and non-stimulants.
9. Visser, S. N., Danielson, M. L., Bitsko, R. H., et al. (2014). Trends in the Parent-Report of Health Care Provider-Diagnosed and Medicated Attention-Deficit/Hyperactivity Disorder: United States, 2003–2011. Journal of the American Academy of Child & Adolescent Psychiatry, 53(1), 34-46.e2.
   • This study offers historical data on the trends of ADHD diagnosis and medication, highlighting the increasing rates over time.
10. González, R. (2023). The Modern Overmedication Crisis: A Look at Psychoactive Drug Use in Adults. Health Affairs Blog.

© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases